Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab
Pembrolizumab is one of the treatment options for treatment-refractory unresectable advanced or metastatic colorectal cancer with microsatellite instability-high (MSI-H) or deficiencies in DNA mismatch repair (dMMR). Herein, we report a case in which a recurrent cecal cancer lesion showed specific i...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Society of Coloproctology
2022-01-01
|
| Series: | Journal of the Anus, Rectum and Colon |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/jarc/6/1/6_2021-053/_pdf/-char/en |
| _version_ | 1818333542245990400 |
|---|---|
| author | Tomohiro Takeda Tatsuya Shonaka Ryotaro Shimazaki Yuki Adachi Masahide Otani Wakako Matsushita Chikayoshi Tani Kimiharu Hasegawa Yasuo Sumi |
| author_facet | Tomohiro Takeda Tatsuya Shonaka Ryotaro Shimazaki Yuki Adachi Masahide Otani Wakako Matsushita Chikayoshi Tani Kimiharu Hasegawa Yasuo Sumi |
| author_sort | Tomohiro Takeda |
| collection | DOAJ |
| description | Pembrolizumab is one of the treatment options for treatment-refractory unresectable advanced or metastatic colorectal cancer with microsatellite instability-high (MSI-H) or deficiencies in DNA mismatch repair (dMMR). Herein, we report a case in which a recurrent cecal cancer lesion showed specific imaging findings and local inflammatory findings during treatment with pembrolizumab, followed by marked shrinkage. The patient was an 80-year-old woman. Postoperative peritoneal recurrence of cecal cancer of approximately 7 cm in size was observed. The patient had MSI-H and was treated with pembrolizumab. After five courses of treatment, the patient presented to our hospital with a chief complaint of abdominal pain. A blood test showed a strong inflammatory reaction, and computed tomography (CT) showed diffuse low-density area in the tumor. Under the suspicion of an abscess, conservative treatment was initiated and the patient quickly recovered. A CT at 1 month showed a marked reduction in size at the same site, and a CT at 3 months showed that the recurrent foci had almost disappeared. The inflammatory reaction before shrinkage in this case may have been caused by tumor immune response to pembrolizumab. |
| first_indexed | 2024-12-13T13:53:17Z |
| format | Article |
| id | doaj.art-7df2eecc9b8f4e27a172a690b9259719 |
| institution | Directory Open Access Journal |
| issn | 2432-3853 |
| language | English |
| last_indexed | 2024-12-13T13:53:17Z |
| publishDate | 2022-01-01 |
| publisher | The Japan Society of Coloproctology |
| record_format | Article |
| series | Journal of the Anus, Rectum and Colon |
| spelling | doaj.art-7df2eecc9b8f4e27a172a690b92597192022-12-21T23:42:59ZengThe Japan Society of ColoproctologyJournal of the Anus, Rectum and Colon2432-38532022-01-0161677110.23922/jarc.2021-0532021-053Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with PembrolizumabTomohiro Takeda0Tatsuya Shonaka1Ryotaro Shimazaki2Yuki Adachi3Masahide Otani4Wakako Matsushita5Chikayoshi Tani6Kimiharu Hasegawa7Yasuo Sumi8Division of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityDivision of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityDivision of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityDivision of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityDivision of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityDivision of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityDivision of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityDivision of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityDivision of Gastrointestinal Surgery, Department of Surgery, Asahikawa Medical UniversityPembrolizumab is one of the treatment options for treatment-refractory unresectable advanced or metastatic colorectal cancer with microsatellite instability-high (MSI-H) or deficiencies in DNA mismatch repair (dMMR). Herein, we report a case in which a recurrent cecal cancer lesion showed specific imaging findings and local inflammatory findings during treatment with pembrolizumab, followed by marked shrinkage. The patient was an 80-year-old woman. Postoperative peritoneal recurrence of cecal cancer of approximately 7 cm in size was observed. The patient had MSI-H and was treated with pembrolizumab. After five courses of treatment, the patient presented to our hospital with a chief complaint of abdominal pain. A blood test showed a strong inflammatory reaction, and computed tomography (CT) showed diffuse low-density area in the tumor. Under the suspicion of an abscess, conservative treatment was initiated and the patient quickly recovered. A CT at 1 month showed a marked reduction in size at the same site, and a CT at 3 months showed that the recurrent foci had almost disappeared. The inflammatory reaction before shrinkage in this case may have been caused by tumor immune response to pembrolizumab.https://www.jstage.jst.go.jp/article/jarc/6/1/6_2021-053/_pdf/-char/encolorectal cancerpembrolizumabmsi-hdmmrperitoneal recurrence |
| spellingShingle | Tomohiro Takeda Tatsuya Shonaka Ryotaro Shimazaki Yuki Adachi Masahide Otani Wakako Matsushita Chikayoshi Tani Kimiharu Hasegawa Yasuo Sumi Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab Journal of the Anus, Rectum and Colon colorectal cancer pembrolizumab msi-h dmmr peritoneal recurrence |
| title | Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab |
| title_full | Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab |
| title_fullStr | Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab |
| title_full_unstemmed | Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab |
| title_short | Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab |
| title_sort | peritoneal recurrence of cecal cancer with specific imaging findings and shrinkage after treatment with pembrolizumab |
| topic | colorectal cancer pembrolizumab msi-h dmmr peritoneal recurrence |
| url | https://www.jstage.jst.go.jp/article/jarc/6/1/6_2021-053/_pdf/-char/en |
| work_keys_str_mv | AT tomohirotakeda peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab AT tatsuyashonaka peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab AT ryotaroshimazaki peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab AT yukiadachi peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab AT masahideotani peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab AT wakakomatsushita peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab AT chikayoshitani peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab AT kimiharuhasegawa peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab AT yasuosumi peritonealrecurrenceofcecalcancerwithspecificimagingfindingsandshrinkageaftertreatmentwithpembrolizumab |